Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  peginterferon alfa-2b
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Ixazomib Citrate and Peginterferon Alfa-2b in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GU-071, NCI-2015-01878, ERP GU-071, NCT02447887
Peginterferon alfa-2b in Treating Younger Patients with Craniopharyngioma That is Recurrent or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 25 years
Trial IDs: PBTC-039, NCI-2013-01639, NCT01964300
Capecitabine or Fluorouracil with Pegylated Interferon Alpha-2b in Treating Patients with Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC 17759, NCI-2014-01864, 14.06.0011, NCT02218164
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 3 to 18
Trial IDs: CHOA2725-14, NCI-2015-00181, IRB00074563, NCT02343224
Pembrolizumab and Peginterferon Alfa-2b in Treating Patients with Advanced Melanoma That Cannot Be Removed By Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-105, NCI-2014-01354, MK-3475, UPCI 13-105, NCT02112032
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GCO 14-1919, NCI-2016-00501, NCT02407080
An Observational Study to Compare the Compliance With Toxicity of Standard High-Dose Interferon A Versus Sylatron
Status: Active
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: Merck MISP 50422, NCI-2015-01266, NCT01986712
Start Over